Actinogen Limited (ASX:ACW) has been granted a trading halt by the ASX pending the results of the CSF clinical data.
The company is focussed on the treatment of Alzheimer’s disease and mild cognitive impairment.
The halt will remain in place until the opening of trade on Wednesday 30th September 2015, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.